cardiovascular Archives -

A study as shown that a smartphone app has been found to be more effective than standard screening

ESC22: Smartphone screening doubles atrial fibrillation detection rate

https://pharmaphorum.com/news/esc22-smartphone-screening-doubles-atrial-fibrillation-detection-rate/

Digital/ News/ News

Digital health app linked to better outcomes in heart failure

Phil Taylor cardiovascular, digital, digital health, HealthStar, heart failure, Pattern Health Technologies 0 Comment

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that

Digital health app linked to better outcomes in heart failure

https://pharmaphorum.com/news/digital-health-app-linked-to-better-outcomes-in-heart-failure/

News/ News/ R&D

NewAmsterdam goes public to advance drug in abandoned class

Phil Taylor cardiovascular, cholesterol, Merck & Co, NewAmsterdam Pharma, obicetrapib, R&D 0 Comment

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier

NewAmsterdam goes public to advance drug in abandoned class

https://pharmaphorum.com/news/newamsterdam-goes-public-to-advance-drug-in-abandoned-class/

News/ News/ R&D

TargED Bio raises €39m for new clot-busting drug

Phil Taylor acquired thrombotic thrombocytopenic purpura, cardiovascular, rare disease, stroke, TargED Biopharmaceuticals, thrombolysis 0 Comment

There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and

TargED Bio raises €39m for new clot-busting drug

https://pharmaphorum.com/news/targed-bio-raises-e39m-for-new-clot-busting-drug/

News/ News/ R&D

Pfizer sees no way forward for Ionis-partnered vupanorsen

Phil Taylor antisense drugs, cardiovascular, Ionis Pharmaceuticals, Pfizer, Regeneron 0 Comment

Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase

Pfizer sees no way forward for Ionis-partnered vupanorsen

https://pharmaphorum.com/news/pfizer-sees-no-way-forward-for-ionis-partnered-vupanorsen/

The critical role of the generics sector during the pandemic

News/ News/ R&D

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

Phil Taylor antisense drugs, cardiovascular, cholesterol, evinacumab, Ionis Pharmaceuticals, Pfizer, Regeneron 0 Comment

Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/

News/ News/ R&D

AZ, Moderna say mRNA drug is promising in heart failure

Phil Taylor AstraZeneca, cardiovascular, heart failure, Moderna, mRNA 0 Comment

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of

AZ, Moderna say mRNA drug is promising in heart failure

https://pharmaphorum.com/news/az-moderna-say-mrna-drug-is-promising-in-heart-failure/

Digital/ News/ News

Smartphone-powered trial backs J&J’s Invokana for heart failure

Phil Taylor cardiovascular, decentralised trials, digital, digital health, heart failure, Invokana, Janssen, Johnson & Johnson 0 Comment

Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms

Smartphone-powered trial backs J&J’s Invokana for heart failure

https://pharmaphorum.com/news/smartphone-powered-trial-backs-jjs-invokana-for-heart-failure/

News/ News/ Sales and Marketing

AZ closes $400 million Atacand sale to Germany’s Cheplapharm

Phil Taylor AstraZeneca, Atacand, cardiovascular, Cheplapharm, Financial 0 Comment

AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as

AZ closes $400 million Atacand sale to Germany’s Cheplapharm

https://pharmaphorum.com/news/az-closes-400-million-atacand-sale-to-germanys-cheplapharm/

Trending

cardiovascular

Login